↓ Skip to main content

Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management

Overview of attention for article published in Drugs, February 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
3 X users
facebook
1 Facebook page

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
43 Mendeley
Title
Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management
Published in
Drugs, February 2018
DOI 10.1007/s40265-018-0879-5
Pubmed ID
Authors

Sebastiano Mercadante

Abstract

The aim of this review is to present the way in which episodic breathlessness (EB) has been recognized over the years, with regard to definition, characteristics, and management of these acute episodes that have serious consequences for patients. EB is characterized by a sudden increase in intensity of dyspnea over a short duration of time, leading to high levels of anxiety. A significant aggravation of dyspnea may occur in patients with a background of dyspnea or intermittently even without basal breathlessness. Often, known precipitating factors may trigger EB. Flares of breathlessness are accompanied by degrees of psychological distress, although it is unclear whether psychological factors may precede or be induced by EB. In any case, there is a reinforcing circuit. The duration of EB ranges from 10-30 min. Given the specific temporal pattern, requiring rapid intervention, substances with a short onset of action are suitable to overlap this phenomenon. Short-onset opioids could provide a clinical effect overlapping the onset and duration of an episode, resembling what has been largely reported for breakthrough pain. Although data are still insufficient to suggest specific recommendations, strategies such as avoiding exertion, pacing or using devices, or keeping calm have been described. Few controlled studies have investigated the effects of different formulations of opioids. Some data were gathered from studies assessing the pre-emptive use of rapid onset opioids, such as transmucosal preparations of fentanyl, followed by a provocative test, while other studies attempted to reproduce real-life conditions, given as needed. All these trials were insufficiently powered to address the efficacy of fentanyl products over oral morphine or placebo, reflecting the difficulties in patient recruiting and finalizing the studies. Strategies to prevent the occurrence of EB should be taken into consideration, including optimization of the condition of persistent dyspnea or treating psychologic or environmental causes.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 43 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 14%
Student > Bachelor 4 9%
Student > Doctoral Student 3 7%
Other 3 7%
Student > Postgraduate 3 7%
Other 7 16%
Unknown 17 40%
Readers by discipline Count As %
Medicine and Dentistry 11 26%
Nursing and Health Professions 4 9%
Psychology 4 9%
Computer Science 1 2%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 5 12%
Unknown 17 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2019.
All research outputs
#14,377,572
of 23,025,074 outputs
Outputs from Drugs
#2,693
of 3,288 outputs
Outputs of similar age
#187,998
of 330,913 outputs
Outputs of similar age from Drugs
#25
of 29 outputs
Altmetric has tracked 23,025,074 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,288 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,913 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.